Fed’s Powell opens door to potential rate cuts at Jackson Hole
On March 4, 2025, Thomas K. Equels, CEO and President of AIM ImmunoTech Inc. (NYSE:AIM), purchased 44,000 shares of the company’s common stock. The insider purchase comes as the stock trades near its 52-week low of $0.11, having declined about 69% over the past year according to InvestingPro data. The shares were acquired at a price of $0.115 each, amounting to a total value of $5,060. Following this transaction, Equels holds a total of 1,808,029 shares directly. This transaction reflects Equels’ continued investment in the company, which specializes in biological products. AIM ImmunoTech, formerly known as Hemispherx Biopharma Inc ., is headquartered in Ocala, Florida. Despite current challenges, analysts maintain optimistic price targets ranging from $1.00 to $4.50, though InvestingPro analysis indicates significant operational hurdles with an EBITDA of -$27.68M in the last twelve months.
In other recent news, AIM ImmunoTech Inc. has received approval from the NYSE American for its compliance plan, giving the company until June 2026 to meet the exchange’s minimum stockholders’ equity requirements. The company had previously been notified of non-compliance due to insufficient stockholders’ equity, prompting the submission of a corrective plan which has now been accepted. Additionally, AIM ImmunoTech is advancing its lead product, Ampligen, as a vaccine adjuvant for avian influenza, in collaboration with Amarex Clinical Research. The company aims to conduct a clinical trial in combination with AstraZeneca (NASDAQ:AZN)’s FluMist, seeking government and industry support to offset study costs. In a strategic move, AIM executives have decided to forgo their 2024 cash bonuses to reallocate resources towards research and development, particularly focusing on Ampligen. This decision was disclosed in a recent SEC filing and reflects the company’s commitment to its R&D objectives. Furthermore, AIM ImmunoTech concluded its 2024 Annual Meeting of Stockholders, where shareholders elected new directors amid a proxy battle, with Nancy K. Bryan and William M. Mitchell receiving the highest votes for company nominees. The meeting also saw the ratification of BDO USA, P.C. as the independent registered public accounting firm for the fiscal year ending December 2024.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.